IMPLライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 12月 2023 @ 05:58):

Stats
本日の出来高	720 030
平均出来高	1.02M
時価総額	956 000
EPS	$0 ( 2024-03-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0128
ATR14	$0.116 (114.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Smith Brandon D	Buy	0
2023-12-15	Vivo Capital Viii, Llc	Sell	87 934	Common Stock
2023-12-18	Vivo Capital Viii, Llc	Sell	209 029	Common Stock
2023-12-19	Vivo Capital Viii, Llc	Sell	208 657	Common Stock
2023-12-15	Vivo Capital Viii, Llc	Sell	12 066	Common Stock

INSIDER POWER
47.38
Last 95 transactions
Buy: 8 739 782 \| Sell: 5 181 184

ボリューム相関

長: 0.42 (neutral)

短: -0.39 (neutral)

Signal:(41.758) Neutral

Impel Pharmaceuticals 相関

10 最も正の相関
FNWB	0.921
EGBN	0.909
CNSL	0.904
DIBS	0.901
ALTO	0.896
FTXO	0.892
FFIC	0.885
FRST	0.883
CSTE	0.881
CCSI	0.88

10 最も負の相関
LMNR	-0.937
WIRE	-0.927
NRDS	-0.918
MHUA	-0.893
PEGA	-0.892
SKYT	-0.889
OBT	-0.889
MORF	-0.886
HTBI	-0.884
HUGE	-0.882

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Impel Pharmaceuticals 相関 - 通貨/商品

0.11
( neutral )

-0.49
( neutral )

0.00
( neutral )

-0.29
( neutral )

0.13
( neutral )

-0.15
( neutral )

Impel Pharmaceuticals 財務諸表

Annual	2022
収益:	$12.65M
総利益:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2022
収益:	$12.65M
総利益:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2021
収益:	$668 000
総利益:	$-23 000.00 (-3.44 %)
EPS:	$-5.25

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Impel Pharmaceuticals

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.